Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Accured Expenses: 2014-2025

Historic Change in Accured Expenses for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to -$4.8 million.

  • Viking Therapeutics' Change in Accured Expenses fell 142.57% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.7 million, marking a year-over-year decrease of 121.25%. This contributed to the annual value of $5.8 million for FY2024, which is 420.26% up from last year.
  • As of Q3 2025, Viking Therapeutics' Change in Accured Expenses stood at -$4.8 million, which was down 132.79% from $14.6 million recorded in Q2 2025.
  • Viking Therapeutics' Change in Accured Expenses' 5-year high stood at $15.9 million during Q1 2024, with a 5-year trough of -$13.6 million in Q2 2024.
  • In the last 3 years, Viking Therapeutics' Change in Accured Expenses had a median value of -$1.6 million in 2023 and averaged $736,545.
  • In the last 5 years, Viking Therapeutics' Change in Accured Expenses slumped by 862.72% in 2023 and then spiked by 6,472.88% in 2024.
  • Over the past 5 years, Viking Therapeutics' Change in Accured Expenses (Quarterly) stood at -$1.1 million in 2021, then spiked by 330.71% to $2.5 million in 2022, then spiked by 57.26% to $3.9 million in 2023, then crashed by 299.80% to -$7.8 million in 2024, then crashed by 142.57% to -$4.8 million in 2025.
  • Its Change in Accured Expenses stands at -$4.8 million for Q3 2025, versus $14.6 million for Q2 2025 and -$5.7 million for Q1 2025.